

Table 1: Patient eligibility criteria for enrolment in studies contributing to the INHALE-HEP meta-trial

Inclusion criteria	<p>Age 18 years or older</p> <p>Currently admitted to hospital</p> <p>There is a PCR positive sample for SARS-CoV-2 within the past 21 days. The sample can be a nasal or pharyngeal swab, sputum, tracheal aspirate, bronchoalveolar lavage, or another sample from the patient</p> <p>Modified ordinal clinical scale 3-5</p>
Exclusion criteria	<p>Intubated and on mechanical ventilation, or requiring immediate intubation as per the treating clinician's assessment</p> <p>Heparin allergy or heparin-induced thrombocytopenia</p> <p>APTT &gt; 120 seconds, not due to anticoagulant therapy and does not correct with administration of fresh frozen plasma</p> <p>Platelet count &lt; 20 x 10<sup>9</sup> per L</p> <p>Pulmonary bleeding or uncontrolled bleeding</p> <p>Pregnant or might be pregnant</p> <p>Acute brain injury that may result in long-term disability</p> <p>Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome</p> <p>Treatment limitations in place, i.e. not for intubation, not for ICU admission</p> <p>Death is imminent or inevitable within 24 hours</p> <p>Clinician objection</p> <p>Refusal of participant (person responsible) consent</p>

PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; APTT, activated partial thromboplastin time; ICU, intensive care unit